Taiwan FDA registration a13b98752387caf3d84638b04a7c8f5f
Qizhe tumor embryonic protein in vitro reagent group
TW: 啟哲腫瘤胚蛋白體外試劑組
Taiwan·Risk Class 2·Longteng Biotechnology Co., Ltd·Registered Dec 11, 2013 – Dec 07, 2016CancelledRegistration details
- Analysis ID
- a13b98752387caf3d84638b04a7c8f5f
Company information
- Manufacturer
- Longteng Biotechnology Co., Ltd
- Manufacturer Country
- Taiwan, Province of China
- Authorized Representative
- Qizhe Biotechnology Co., Ltd
Product details
- Intended Use
- Qualitative detection of tumor embryo protein (CEA) in human serum.
- Product Type (Level 1)
- C Immunology and microbiology
- Product Type (Level 2)
- C.6010 腫瘤相關抗原免疫試驗系統
- Import Information
- Domestic;; Contract manufacturing
Dates and status
- Registration Date
- Dec 11, 2013
- Expiry Date
- Dec 07, 2016
- Cancellation Date
- Apr 25, 2018
Cancellation information
- Status
- Logged out
- Reason
- 自行鍵入
About this record
Access comprehensive regulatory information for Qizhe tumor embryonic protein in vitro reagent group in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number a13b98752387caf3d84638b04a7c8f5f and manufactured by Longteng Biotechnology Co., Ltd. The authorized representative in Taiwan is Qizhe Biotechnology Co., Ltd.
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices